RISK COMMUNICATION

Deborah Shatin, Nigel S B Rawson, Jeffrey R Curtis, M Miles Braun, Carolyn K Martin, Larry W Moreland, Angela F Becker, Nivetita M Patkar, Jeroan J Allison, and Kenneth G Saag. (2005). "Documented tuberculin skin testing among Infliximab users following multi-modal risk communication interventions,” Pharmacoepidemiology and Drug Safety. 14:149-154.

Deborah Shatin, Jacqueline S Gardner, Andy Stergachis, David Blough, and David Graham. (2005). “Impact of mailed warning to prescribers on the co-prescription of Tramadol
and antidepressants,” Pharmacoepidemiology and Drug Safety. 14:149-154.

Mary E Willy, Bharati Manda, Deborah Shatin, Carol Drinkard, and David Graham. (2002). “A study of compliance with FDA recommendations for Pemoline (Cylert®).” Journal of the
American Academy of Child & Adolescent Psychiatry. 41(7):785-790.

David J. Graham, Carol R Drinkard, Deborah Shatin, Yi Tsong, and Margaret J Burgess. (2001). “Liver enzyme monitoring in patients treated with Troglitazone.” JAMA. 286(7):831-833.

Walter Smalley, Deborah Shatin, Diane K Wysowski, Jerry Gurwitz, Susan E Andrade, Michael Goodman, K Arnold Chan, Richard Platt, Stephanie D Schech and Wayne A Ray. (2000). "Contraindicated use of Cisapride: The impact of an FDA regulatory action." JAMA. 284(23):3036-3039.